Evelyn Brandt-Wouters1, Oliver H H Gerlach2, Raymond M M Hupperts3. 1. Neurology, Maastricht Universitair Medisch Centrum, Maastricht, Netherlands. 2. Neurology, Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands. Electronic address: ol.gerlach@orbisconcern.nl. 3. Neurology, Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands.
Abstract
OBJECTIVE: To evaluate the effect of intravenous immunoglobulins (IVIGs) on the expected increase in postpartum relapse rate (RR) among patients with multiple sclerosis (MS). METHODS: In a retrospective study, data were analyzed from patients with relapsing remitting MS who received postpartum IVIG at the Academic MS Center Limburg, Sittard-Geleen, Netherlands, between April 2005 and January 2015. Patients received 10g IVIG (Nanogam) for 3 consecutive days after childbirth, and then once monthly until 5months after delivery. Data were compared with results from the Pregnancy in Multiple Sclerosis (PRIMS) I and II studies, which followed the natural outcomes of patients with MS with no intervention. RESULTS: Overall, 42 pregnancies were evaluated. The RR in the first 3months after delivery was 0.48±1.31, as compared with 1.2 in the PRIMS studies. The RR also remained low at 3-6, 6-9, and 9-12months after delivery for patients who received IVIG. CONCLUSION: Postpartum administration of IVIG could be beneficial in preventing childbirth-associated relapses among patients with MS. It led to a substantial decrease in RR.
OBJECTIVE: To evaluate the effect of intravenous immunoglobulins (IVIGs) on the expected increase in postpartum relapse rate (RR) among patients with multiple sclerosis (MS). METHODS: In a retrospective study, data were analyzed from patients with relapsing remitting MS who received postpartum IVIG at the Academic MS Center Limburg, Sittard-Geleen, Netherlands, between April 2005 and January 2015. Patients received 10g IVIG (Nanogam) for 3 consecutive days after childbirth, and then once monthly until 5months after delivery. Data were compared with results from the Pregnancy in Multiple Sclerosis (PRIMS) I and II studies, which followed the natural outcomes of patients with MS with no intervention. RESULTS: Overall, 42 pregnancies were evaluated. The RR in the first 3months after delivery was 0.48±1.31, as compared with 1.2 in the PRIMS studies. The RR also remained low at 3-6, 6-9, and 9-12months after delivery for patients who received IVIG. CONCLUSION: Postpartum administration of IVIG could be beneficial in preventing childbirth-associated relapses among patients with MS. It led to a substantial decrease in RR.
Authors: Bridget LaMonica Ostrem; Annika Anderson; Sarah Conway; Brian C Healy; Jiwon Oh; Dina Jacobs; Ruth Dobson; Edith Larmon Graham; A Dessa Sadovnick; Vanessa Zimmerman; Yanqing Liu; Riley Bove; Maria Houtchens Journal: Mult Scler J Exp Transl Clin Date: 2022-06-15